Personalis Inc
NASDAQ:PSNL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Personalis Inc
NASDAQ:PSNL
|
US |
|
Ressources Minieres Radisson Inc
XTSX:RDS
|
CA |
|
Serial Achieva Ltd
SGX:XHV
|
MY |
|
E
|
ETSY Inc
LSE:0IIW
|
US |
Personalis Inc
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.
Clinical Volume Surge: Personalis delivered 6,183 clinical tests in Q4 2025, a 41% increase over Q3 and 329% growth year-over-year, with annual clinical volumes up 394%.
Revenue: Q4 2025 revenue was $17.3 million, in line with last month's preliminary announcement; full-year revenue was $69.6 million, reflecting a shift to higher-value MRD work.
Medicare Coverage: Achieved Medicare coverage for breast and lung cancer, validating Personalis' technology and supporting future growth.
2026 Guidance: Expects $78–80 million in 2026 revenue, with clinical test volumes projected at 43,000–45,000, about 170% growth year-over-year.
Margin Outlook: Gross margin fell to 11% in Q4 (22.7% for the year) due to unreimbursed tests but is expected to recover as reimbursement grows; 2026 margin guidance is 15–20%.
Strong Balance Sheet: Ended 2025 with $240 million in cash and short-term investments and guided to ~$100 million cash use in 2026, supporting aggressive growth.
Biopharma MRD Momentum: Biopharma MRD revenue grew almost 240% in 2025, with 2026 MRD pharma/biopharma revenue expected at $20–21 million.
Evidence & Expansion: Personalis is leading or participating in over 35 studies, aiming to further drive coverage and clinical adoption.
